Material Event (Form 8-K)

Artiva Biotherapeutics, Inc. (the "Company") today announced that the expected date for the Company's 2026 annual meeting of stockholders (the "Annual Meeting") is September 8, 2026, which is more than 70 days after the one-year anniversary of the Company's 2025 annual meeting of stockholders. In light of the foregoing, and in accordance with the Company's amended and restated bylaws (the "Bylaws"), in order for any business to be brought before the Annual Meeting by a stockholder and for any person to be nominated for election to the Company's board of directors at the Annual Meeting by a stockholder, such stockholder must notify the Company of such intention by notice received at the Company's principal executive offices not later than the close of business on August 1, 2026. In addition, stockholder proposals intended for inclusion in the Company's proxy statement for the Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must be received at the Company's principal executive offices no later than the close of business on August 1, 2026, which the Company believes is a reasonable time before it begins to print and mail proxy materials for the Annual Meeting. In addition, all such stockholder notices and stockholder proposals must conform to the applicable requirements of the Bylaws, the rules and regulations promulgated under the Exchange Act and other applicable law. All such notices and stockholder proposals are to be directed to: Artiva Biotherapeutics, Inc., Attention: Secretary, 5505 Morehouse Drive, Suite 100, San Diego, California 92121.